SK Biopharmaceuticals Co Ltd (326030) · Other

D&D Pharmatech Inc (347850) · Other

Top-line results from the Phase 2 clinical trial of MASH treatment candidate DD01, including 48-week liver biopsy data, are scheduled to be announced around May 2026. High importance is estimated due to the potential for significant price impact (≥10%) upon the release of Phase 2 clinical trial results scheduled

5/31/2026, 12:00:00 AM

Yuhan Corp (000100) · Other

The 103rd Annual General Meeting to approve FY2025 financial statements and a cash dividend of KRW 600 per common share on March 20, 2026, with minimal market impact anticipated, is scheduled.

3/20/2026, 12:00:00 AM

LigaChem Biosciences Inc (141080) · Other

Presentation of preclinical results for two next-generation BCMA-targeting ADC candidates at the AACR Annual Meeting scheduled. Expected impact is Medium as major conference presentations typically influence biotech valuations.

3/18/2026, 12:00:00 AM

Daewoong Pharmaceutical Co Ltd (069620) · Other

In its 2025 annual report filed on March 18, 2026, the company removed its '1 Product, 1 Trillion KRW Sales' slogan, shifting its strategic focus to fostering multiple global blockbuster drugs; low market impact from strategic shift is expected.

3/18/2026, 12:00:00 AM

Hanmi Pharm Co Ltd (128940) · Other

Announced a shareholder return plan on March 16, 2026, to be proposed at the March 31 AGM, including the cancellation of 85,316 treasury shares and a record-high cash dividend; expected to cause a >10% price impact due to significant shareholder value enhancement expected.

3/16/2026, 12:00:00 AM

GC Cell Corporation (144510) · Earnings Release

Announced full-year 2025 earnings results, reporting a significant increase in net loss to KRW 272.9 billion from KRW 73.9 billion in the previous year. Basic loss per share widened to KRW 18,158 from KRW 4,918.

3/16/2026, 12:00:00 AM